Lev Feodosyev - PAO NOVATEK First Board
| NSTKFDelisted Stock | USD 22.29 0.00 0.00% |
Insider
Lev Feodosyev is First Board of PAO NOVATEK
| Age | 44 |
| Phone | 7 3499 72 49 51 |
| Web | https://www.novatek.ru |
PAO NOVATEK Management Efficiency
The company has return on total asset (ROA) of 0.0772 % which means that it generated a profit of $0.0772 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2544 %, meaning that it generated $0.2544 on every $100 dollars invested by stockholders. PAO NOVATEK's management efficiency ratios could be used to measure how well PAO NOVATEK manages its routine affairs as well as how well it operates its assets and liabilities.PAO NOVATEK has accumulated 67.01 B in total debt with debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. PAO NOVATEK has a current ratio of 2.61, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist PAO NOVATEK until it has trouble settling it off, either with new capital or with free cash flow. So, PAO NOVATEK's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PAO NOVATEK sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PAO to invest in growth at high rates of return. When we think about PAO NOVATEK's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Sierk Poetting | BioNTech SE | 51 | |
| MD MSc | Centessa Pharmaceuticals PLC | 64 | |
| Gina Boswell | Acco Brands | 58 | |
| Thomas Templeman | Centessa Pharmaceuticals PLC | 64 | |
| John Parks | Franklin Wireless Corp | N/A | |
| Ozlem MD | BioNTech SE | 57 | |
| E Rajkowski | Acco Brands | 62 | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
| Angela Jones | Acco Brands | 60 | |
| Wang Wei | Weibo Corp | 50 | |
| David Chao | Centessa Pharmaceuticals PLC | 56 | |
| Iqbal LLB | Centessa Pharmaceuticals PLC | 43 | |
| Karen Anderson | Centessa Pharmaceuticals PLC | 56 | |
| Sarah Luna | Xponential Fitness | 37 | |
| Tia Bush | Centessa Pharmaceuticals PLC | 53 | |
| Roxanne Bernstein | Acco Brands | 46 | |
| David Grainger | Centessa Pharmaceuticals PLC | 55 | |
| Sandra Zhang | Weibo Corp | N/A | |
| Jens Holstein | BioNTech SE | 61 | |
| Ryan Richardson | BioNTech SE | 45 | |
| Chelsea Grayson | Xponential Fitness | 49 | |
Management Performance
| Return On Equity | 0.25 | |||
| Return On Asset | 0.0772 |
PAO NOVATEK Leadership Team
Elected by the shareholders, the PAO NOVATEK's board of directors comprises two types of representatives: PAO NOVATEK inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PAO. The board's role is to monitor PAO NOVATEK's management team and ensure that shareholders' interests are well served. PAO NOVATEK's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PAO NOVATEK's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sergey Vasyunin, Deputy Director | ||
| Viktor Belyakov, Deputy Fin | ||
| Eduard Gudkov, Deputy Board | ||
| Lev Feodosyev, First Board | ||
| Vladimir Baskov, Deputy Board | ||
| Leonid Mikhelson, Chairman CEO | ||
| Ilya Tafintsev, Deputy Board | ||
| Tatyana Kuznetsova, Deputy Board | ||
| Mark Gyetvay, Deputy Board | ||
| Denis Solovyov, Deputy Board |
PAO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PAO NOVATEK a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.25 | |||
| Return On Asset | 0.0772 | |||
| Profit Margin | 0.41 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 68.11 B | |||
| Shares Outstanding | 3 B | |||
| Shares Owned By Insiders | 41.09 % | |||
| Shares Owned By Institutions | 2.44 % | |||
| Price To Earning | 2.22 X | |||
| Price To Book | 2.16 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in PAO Pink Sheet
If you are still planning to invest in PAO NOVATEK check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PAO NOVATEK's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |